Sholpan Askarova

Dr. Sholpan Askarova

National Laboratory Astana
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DADauren Alimbetov
Dauren Alimbetov
SASholpan Askarova
Sholpan Askarova
BUBauyrzhan Umbayev
Bauyrzhan Umbayev
TDTerence Davis
Terence Davis
DKDavid Kipling
David Kipling
Chemotherapeutic drugs target a physiological differentiating feature of cancer cells as they tend to actively proliferate more than normal cells. They have well-known side-effects resulting from the death of highly proliferative normal cells in the gut and immune system. Cancer treatment has changed dramatically over the years owing to rapid advances in oncology research. Developments in cancer therapies, namely surgery, radiotherapy, cytotoxic chemotherapy and selective treatment methods due to better understanding of tumor characteristics, have significantly increased cancer survival. However, many chemotherapeutic regimes still fail, with 90% of the drug failures in metastatic cancer treatment due to chemoresistance, as cancer cells eventually develop resistance to chemotherapeutic drugs. Chemoresistance is caused through genetic mutations in various proteins involved in cellular mechanisms such as cell cycle, apoptosis and cell adhesion, and targeting those mechanisms could improve outcomes of cancer therapy. Recent developments in cancer treatment are focused on combination therapy, whereby cells are sensitized to chemotherapeutic agents using inhibitors of target pathways inducing chemoresistance thus, hopefully, overcoming the problems of drug resistance. In this review, we discuss the role of cell cycle, apoptosis and cell adhesion in cancer chemoresistance mechanisms, possible drugs to target these pathways and, thus, novel therapeutic approaches for cancer treatment.


1 December 2010 in Neuroscience
Verified
Journal Article
Closed access
XYX. Yang
X. Yang
SASholpan Askarova
Sholpan Askarova
WSW. Sheng
W. Sheng
JCJ.K. Chen
J.K. Chen
ASA.Y. Sun
A.Y. Sun
JLJ.C.-M. Lee
J.C.-M. Lee

21 March 2023 in Toxins
Verified
Journal Article
Open access
PDF file
GNGalina Nugumanova
Galina Nugumanova
Eugene D. PonomarevEugene D. Ponomarev
Eugene D. Ponomarev
SASholpan Askarova
Sholpan Askarova
EFElizaveta Fasler
Elizaveta Fasler
NBNatasha S. Barteneva
Natasha S. Barteneva
Cyanobacteria produce a wide range of structurally diverse cyanotoxins and bioactive cyanopeptides in freshwater, marine, and terrestrial ecosystems. The health significance of these metabolites, which include genotoxic- and neurotoxic agents, is confirmed by continued associations between the occurrence of animal and human acute toxic events and, in the long term, by associations between cyanobacteria and neurodegenerative diseases. Major mechanisms related to the neurotoxicity of cyanobacteria compounds include (1) blocking of key proteins and channels; (2) inhibition of essential enzymes in mammalian cells such as protein phosphatases and phosphoprotein phosphatases as well as new molecular targets such as toll-like receptors 4 and 8. One of the widely discussed implicated mechanisms includes a misincorporation of cyanobacterial non-proteogenic amino acids. Recent research provides evidence that non-proteinogenic amino acid BMAA produced by cyanobacteria have multiple effects on translation process and bypasses the proof-reading ability of the aminoacyl-tRNA-synthetase. Aberrant proteins generated by non-canonical translation may be a factor in neuronal death and neurodegeneration. We hypothesize that the production of cyanopeptides and non-canonical amino acids is a more general mechanism, leading to mistranslation, affecting protein homeostasis, and targeting mitochondria in eukaryotic cells. It can be evolutionarily ancient and initially developed to control phytoplankton communities during algal blooms. Outcompeting gut symbiotic microorganisms may lead to dysbiosis, increased gut permeability, a shift in blood-brain-barrier functionality, and eventually, mitochondrial dysfunction in high-energy demanding neurons. A better understanding of the interaction between cyanopeptides metabolism and the nervous system will be crucial to target or to prevent neurodegenerative diseases.

1 May 2010 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
XYXiaoguang Yang
Xiaoguang Yang
SASholpan Askarova
Sholpan Askarova
JLJames C-M. Lee
James C-M. Lee
Alzheimer's disease is a chronic neurodegenerative disorder characterized by neuronal loss, cerebrovascular inflammation, and accumulation of senile plaques in the brain parenchyma and cerebral blood vessels. Amyloid-β peptide (Aβ), a major component of senile plaques, has been shown to exert multiple toxic effects to neurons, astrocytes, glial cells, and brain endothelium. Oligomeric Aβ can disturb the structure and function of cell membranes and alter membrane mechanical properties, such as membrane fluidity and molecular order. Much of these effects are attributed to their capability to trigger oxidative stress and inflammation. In this review, we discuss the effects of Aβ on neuronal cells, astrocytes, and cerebral endothelial cells with special emphasis on cell membrane properties and cell functions.

1 November 2014 in Biomaterials
Verified
Journal Article
Closed access
SDSonia D'Souza
Sonia D'Souza
HMHironobu Murata
Hironobu Murata
MJMoncy V. Jose
Moncy V. Jose
SASholpan Askarova
Sholpan Askarova
YYYuliya Yantsen
Yuliya Yantsen
ARAlan J. Russell
Alan J. Russell